Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment

被引:0
|
作者
King-Concialdi, Kristen [1 ]
Beusterien, Kathleen [1 ]
Senglaub, Steven S. [1 ,4 ]
Will, Oliver [1 ]
Jaffe, Dena H. [1 ]
Patel, Miraj Y. [2 ]
Harrison, Michael R. [3 ]
机构
[1] Cerner Enviza, Oracle Co, Real World Evidence, North Kansas City, MO USA
[2] Bristol Myers Squibb, Hlth Econ & Outcomes Res, Princeton, NJ USA
[3] Duke Univ, Med Ctr, Ctr Prostate & Urol Canc, Duke Canc Inst,Dept Med,Div Med Oncol, Durham, NC USA
[4] Cerner Enviza, Oracle Co, Real World Evidence, 2800 Rock Creek Pkwy, North Kansas City, MO 64117 USA
来源
关键词
bladder cancer; discrete choice experiment; muscle-invasive urothelial carcinoma; patient treatment preferences; NEOADJUVANT CHEMOTHERAPY; IMMUNOTHERAPY; NIVOLUMAB; THERAPY;
D O I
10.2147/PPA.S411751
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The evolving treatment landscape in muscle-invasive urothelial carcinoma creates challenges for clinicians and patients in selecting the most appropriate therapy. Here, we aimed to understand adjuvant treatment preferences among patients with muscle invasive urothelial carcinoma who underwent radical resection, including tradeoffs between efficacy outcomes and toxicity risks. Patients and Methods: An observational, cross-sectional study utilizing a discrete choice experiment was conducted across the United States, United Kingdom, Canada, France, and Germany via a web-based survey. Patients >= 18 years of age who self-reported as having been diagnosed with muscle-invasive urothelial carcinoma were included. Patients indicated their preferences between hypothetical treatment profiles varying in eight attributes relating to efficacy, regimen, and side effects. Preference weights were estimated using hierarchical Bayesian logistic regression; relative attribute importance estimates were calculated. Results: Overall, 207 patients were included (age >= 56 years, 65.7%; male, 54.1%). Patients chose adjuvant treatment 91.2% of the time vs no treatment. Prolonging overall survival from 25 to 78 months was most important, followed by reducing serious side effect risks. Increasing disease-free survival from 12 to 24 months was more important than decreasing risks of fatigue from 54% to 15% and nausea from 53% to 7%. Treatment with the shortest dosing regimen was more important for patients who received neoadjuvant chemotherapy vs patients who did not receive neoadjuvant chemotherapy; prolonging overall survival was more important than reducing the risk of a serious side effect in non-US patients; the opposite was found in the United States. Conclusion: Patients with muscle-invasive urothelial carcinoma who underwent radical resection preferred adjuvant treatment over no treatment regardless of side effects. Patients prioritized overall survival improvements followed by a reduced side effect profile.
引用
收藏
页码:2237 / 2248
页数:12
相关论文
共 50 条
  • [21] Patient Preferences in Subglottic Stenosis Treatment: A Discrete Choice Experiment
    Naunheim, Matthew R.
    Naunheim, Margaret L.
    Rathi, Vinay K.
    Franco, Ramon A.
    Shrime, Mark G.
    Song, Phillip C.
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2018, 158 (03) : 520 - 526
  • [22] Patient preferences for treatment of psoriasis with biologics: a discrete choice experiment
    Kromer, C.
    Schaarschmidt, M. -L.
    Schmieder, A.
    Herr, R.
    Goerdt, S.
    Peitsch, W. K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E125 - E125
  • [23] Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment
    Schaarschmidt, M. L.
    Kromer, C.
    Herr, R.
    Schmieder, A.
    Goerdt, S.
    Peitsch, W. K.
    [J]. EXPERIMENTAL DERMATOLOGY, 2015, 24 (03) : E18 - E18
  • [24] Patient Preferences for Cholesterol Treatment Options: A Discrete Choice Experiment
    Lewey, Jennifer
    Choudhry, Niteesh K.
    Gagne, Joshua J.
    Avorn, Jerry
    Najafzadeh, Mehdi
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 157 - 157
  • [25] Patient preferences for the treatment of chronic cough: a discrete choice experiment
    Swaminathan, Aparna C.
    Yang, Jui-Chen
    Ding, Helen
    Grover, Kiran
    Coles, Theresa
    Schelfhout, Jonathan
    Johnson, F. Reed
    [J]. BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)
  • [26] Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
    Kromer, Christian
    Schaarschmidt, Marthe-Lisa
    Schmieder, Astrid
    Herr, Raphael
    Goerdt, Sergij
    Peitsch, Wiebke K.
    [J]. PLOS ONE, 2015, 10 (06):
  • [27] COST-EFFECTIVENESS OF NIVOLUMAB AS AN ADJUVANT TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA AT HIGH RISK OF RECURRENCE IN SWITZERLAND
    Oniangue-Ndza, C.
    Kamgar, F.
    Schneider, R. P.
    Teitsson, S.
    Knight, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S146 - S146
  • [28] Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder
    Hensley, Patrick J.
    Goodwin, Jeffrey
    Davenport, Daniel L.
    Strup, Stephen E.
    James, Andrew
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E851 - E858
  • [29] Household preferences for private versus public subsidies for new heating systems: insights from a multi-country discrete choice experiment
    Schleich, Joachim
    Guetlein, Marie-Charlotte
    Tu, Gengyang
    Faure, Corinne
    [J]. APPLIED ECONOMICS, 2022, 54 (37) : 4292 - 4309
  • [30] Patient preferences for the attributes of a noninvasive treatment for superficial basal cell carcinoma: a discrete choice experiment
    Essers, B. A. B.
    Arits, A. H.
    Hendriks, M. R.
    Mosterd, K.
    Kelleners-Smeets, N. W.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : E26 - E27